Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03706014 · ClinicalTrials.gov registry record · NA
Innovative Family Prevention With Latino Siblings in Disadvantaged Settings
A NA study of Promotion of Positive Sibling Relationships, sponsored by Harvard University.
- Active
- Registry status
- NA
- Development phase
- 270
- Enrollment target
- 1
- Study location
NCT03706014: Active NA study of Promotion of Positive Sibling Relationships, sponsored by Harvard University.
NCT03706014 is a NA study of Promotion of Positive Sibling Relationships that is active but no longer recruiting, run by Harvard University. The registered enrollment target is 270 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03706014, a NA study of Promotion of Positive Sibling Relationships, is active but no longer recruiting, sponsored by Harvard University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 270 participants
- Enrollment target
- 1
- Study location
Study Summary
The current study is a randomized intervention trial that tests the efficacy of a family-focused sibling relationship promotion program. The study includes a treatment group and a contact-equivalent attention control condition with 288 sibling dyads and data collection with target parents, target sibling dyads, and teachers at three time points (pre-test, post-test, and 18-month follow-up). Data will be collected using a three-cohort design with 96 families in each of the three cohorts.
Primary Outcome
The measure assesses parents' perceptions of three constructs: Parents' positive guidance, authoritarian control, and involvement (McHale et al., 2000; Updegraff et al., 2016). For each subscale, scores range from 1 to 5. Higher subscale scores indicate more positive guidance (i.e., better outcome), higher involvement (i.e., better outcome), and higher authoritarian control (i.e., worse outcome). Subscales are not combined into a total score.
Conditions Studied
Interventions
- BEHAVIORAL Control
- BEHAVIORAL SIBS Program
Study Locations (1)
Arizona
- Arizona State University - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2018-09-29 |
| Est. Completion | 2025-12-15 |
| Phase | NA |
What the registry record for NCT03706014 still lists
NCT03706014 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Promotion of Positive Sibling Relationships appearing as the primary indexed condition, and to 2 interventions - of which Control is the first listed.
NCT03706014 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT03706014 about?
NCT03706014 is a clinical study titled "Innovative Family Prevention With Latino Siblings in Disadvantaged Settings". The current study is a randomized intervention trial that tests the efficacy of a family-focused sibling relationship promotion program. The study includes a treatment group and a contact-equivalent attention control condition with 288 sibling dyads and data collection with target parents, target si...
What is the current status of trial NCT03706014?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 270 participants. The study started on 2018-09-29. Estimated completion is 2025-12-15.
What conditions does trial NCT03706014 study?
This clinical trial studies the following conditions: Promotion of Positive Sibling Relationships.
What interventions are being tested in trial NCT03706014?
The interventions under investigation include: Control (BEHAVIORAL), SIBS Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT03706014?
This trial is sponsored by Harvard University, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03706014 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03706014's enrollment target sits among peer trials
270 387th of 2000 higher than 1,609 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI